Form 4: IGM Biosciences Director Acquires Shares as Part of Compensation Plan

Director M Kathleen Behrens acquired 3,078 shares of IGM Biosciences common stock as part of a quarterly retainer, while also reporting indirect ownership through various trusts.

Summary

• On March 29, 2024, M Kathleen Behrens, a director of IGM Biosciences, acquired 3,078 shares of common stock.
• This acquisition was part of a quarterly retainer paid in common stock, according to the Issuer's Outside Director Compensation Policy.
• The price per share for this acquisition was $0.
• Following the transaction, Behrens directly owns 10,046 shares.
• Behrens also indirectly owns 330,700 shares through the KBW 2005 Trust, where she serves as Trustee.
• Additionally, she indirectly owns 29,807 shares and 29,806 shares through Non-Exempt Trusts for Patrick R. Wilsey and Shannon K. Wilsey, respectively, under the Alfred S. Wilsey, Jr. Revocable Trust, where she is also a Trustee.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document reports a routine transaction related to director compensation. There is no indication of significant positive or negative news.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.
• The use of common stock for director compensation aligns the director's interests with those of the shareholders.

Industry Context

Director share acquisitions are a common occurrence in publicly traded companies and are often viewed as a sign of confidence in the company's future.

Stakeholder Impact

• The acquisition of shares by a director may have a slightly positive impact on shareholder sentiment.

Key Dates